• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

478 what kind of direct oral anticoagulant presents the lowest bleeding risk after endoscopic resection of colorectal polyps?
Direct oral anticoagulants (DOACs), including dabigatran, rivaroxaban, apixaban, and edoxaban, have become popular as equivalent to warfarin for stroke prevention in non-valvular atrial fibrillation; however, bleeding risk from DOACs, especially the difference in risks among DOACs in endoscopic treatment, has not been reported. The study aimed to evaluate delayed bleeding risk related to early resumption of DOACs and compare the bleeding risk among DOACs after endoscopic resection of colorectal polyps.
Source: Gastrointestinal Endoscopy - May 31, 2019 Category: Gastroenterology Authors: Kazuko Beppu, Kazunori Yokoi, Hisafumi Yamagata, Satoko Suzuki, Tatsuo Ogihara Tags: Oral abstract Source Type: research

Mo1133 PROSPECTIVE EVALUATION OF 30-DAY BLEEDING AND THROMBOEMBOLIC RISKS IN PATIENTS UNDERGOING COLONOSCOPY WHILE TAKING WARFARIN OR NOVEL ANTICOAGULANTS
With the rising prevalence of ischemic heart disease and atrial fibrillation as well as the expanding indications on the use of anticoagulants, there are increasing number of patients undergoing colonoscopies while on these agents. International societies issued guidelines on the peri-endoscopic management of the anticoagulants but little is known on the actual outcome of these patients, particularly those taking novel anti-coagulants (NOACs). We aim to prospectively evaluate the 30-day morbidities (gastrointestinal bleeding, stroke and cardiovascular complications) and mortalities of patients taking warfarin, NOACs and/or...
Source: Gastrointestinal Endoscopy - May 30, 2018 Category: Gastroenterology Authors: Sze Hang Kevin Liu, Lijia Chen, Sze Kan Leung, Wai K. Leung Tags: Monday abstract Source Type: research

Mo1090 DIRECT-ACTING ORAL ANTICOAGULANT (DOAC) USE IS NOT ASSOCIATED WITH INCREASED RISK OF COMPLICATIONS AFTER POLYPECTOMY
Direct-acting oral anticoagulants (DOACs) such as rivaroxaban, apixaban, dabigatran, and edoxaban represent 62% of new anticoagulation prescriptions. Compared to warfarin, DOACs increase the risk of gastrointestinal bleeding but reduce the risk of stroke. Little is known about the risk of complications after polypectomy in patients with active DOAC use. We aimed to determine the risk of complications after polypectomy in this population.
Source: Gastrointestinal Endoscopy - May 30, 2018 Category: Gastroenterology Authors: Jessica X. Yu, Melissa Oliver, Jody Lin, Matthew S. Chang, Allison J. Kwong, Berkeley Limketkai, Roy M. Soetikno, Jayanta Bhattacharya, Tonya R. Kaltenbach Tags: Monday abstract Source Type: research

New predictive model for acute gastrointestinal bleeding in patients taking oral anticoagulants: A cohort study
ConclusionsGastrointestinal bleeding increased the risk of subsequent mortality during follow‐up of anticoagulated patients, highlighting the importance of prevention. The study developed a new scoring model for acute GI bleeding risk based on five factors (no‐proton pump inhibitor use, chronic kidney disease, chronic obstructive pulmonary disease, history of peptic ulcer disease, and liver cirrhosis), which was superior to the HAS‐BLED score.
Source: Journal of Gastroenterology and Hepatology - December 28, 2017 Category: Gastroenterology Authors: Akira Shimomura, Naoyoshi Nagata, Takuro Shimbo, Toshiyuki Sakurai, Shiori Moriyasu, Hidetaka Okubo, Kazuhiro Watanabe, Chizu Yokoi, Junichi Akiyama, Naomi Uemura Tags: Gastroenterology Source Type: research

Su1162 Gastrointestinal Bleeding With Warfarin, Novel Oral Anticoagulants and Left Atrial Appendage Exclusion Device in Patients With Atrial Fibrillation: Network Meta-Analysis of Randomized Controlled Trials
Novel oral anticoagulants (NOAC) are extensively being used in atrial fibrillation (AF) patients for mitigating stroke risk as an alternative to warfarin. In those patients with higher bleeding risk, left atrial appendage exclusion devices are being used for decreasing stroke risk. We performed a network meta-analysis of all randomized controlled trials (RCT) to compare the relative efficacy of all these agents.
Source: Gastrointestinal Endoscopy - April 28, 2017 Category: Gastroenterology Authors: Avanija Buddam, Arun Kanmanthareddy, Sunil Dacha, Sandeep Mukherjee, Savio Reddymasu Tags: Sunday – ASGE poster Source Type: research

Mo1086 Severity of Gastrointestinal Bleeding in Patients Treated With Direct-Acting Oral Anticoagulants (Doacs)
Direct-acting oral anticoagulants (DOACs), which have recently been approved for stroke prevention in non-valvular atrial fibrillation and treatment of venous thromboembolism, have become increasingly preferred over warfarin given their predictable pharmacodynamics and lack of required monitoring. DOACs have been shown to be associated with an increased frequency of gastrointestinal bleeding (GIB) compared to warfarin, but the severity of GIB in these patients is poorly understood.
Source: Gastrointestinal Endoscopy - April 28, 2017 Category: Gastroenterology Authors: Mark M. Brodie, Tyler Smith, Jill Newman, Don C. Rockey Tags: Monday – ASGE poster Source Type: research

Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management.
Abstract Novel oral anticoagulants (NOACs), which include direct thrombin inhibitor (dabigatran) and direct factor Xa inhibitors (rivaroxaban, apixaban and edoxaban), are gaining popularity in the prevention of embolic stroke in non-valvular atrial fibrillation as well as in the prevention and treatment of venous thromboembolism. However, similar to traditional anticoagulants, NOACs have the side effects of bleeding, including gastrointestinal bleeding (GIB). Results from both randomized clinical trials and observations studies suggest that high-dose dabigatran (150 mg b.i.d), rivaroxaban and high-dose edoxaban (6...
Source: World Journal of Gastroenterology : WJG - March 21, 2017 Category: Gastroenterology Authors: Cheung KS, Leung WK Tags: World J Gastroenterol Source Type: research

Gastrointestinal Bleeding and Direct Oral Anticoagulants Amongst Patients With Atrial Fibrillation in the “Real World”
The pivotal aim of oral anticoagulation in atrial fibrillation (AF) is prevention of AF-related thromboembolic strokes. The vitamin K antagonists (eg, warfarin) have been the standard of care for many years, reducing both stroke and mortality rates by 64% and 26% respectively, compared with placebo/control.1 Approval and market release of direct oral anticoagulants (DOACs; also referred to as non-vitamin K antagonist oral anticoagulants2), such as dabigatran, rivaroxaban, apixaban, and edoxaban, have changed the landscape of thromboprophylaxis substantially.
Source: Gastroenterology - February 28, 2017 Category: Gastroenterology Authors: Micha ł Mazurek, Gregory Y.H. Lip Tags: Editorial Source Type: research

Gastrointestinal Bleeding With Oral Anticoagulation: Understanding the Scope of the Problem
Systemic anticoagulation with vitamin K antagonists or direct-acting oral anticoagulants (DOACs) remains the mainstay of therapy to attenuate the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF). Given more predictable pharmacology, use of fixed-dose regimens, and lack of need for routine drug monitoring, DOACs have enjoyed relatively high uptake and quickly have become integrated into clinical practice.1 Although these agents generally have a favorable index of safety in comparison with warfarin with a lower risk of intracranial hemorrhage, rates of major gastrointestinal (GI) b...
Source: Clinical Gastroenterology and Hepatology - January 13, 2017 Category: Gastroenterology Authors: Muthiah Vaduganathan, Deepak L. Bhatt Tags: Editorial Source Type: research

Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation
Gastrointestinal (GI) bleeding in patients receiving anticoagulation agents can be caused by occult malignancies. We investigated the proportions and features of major GI bleeding (MGIB) events related to occult GI cancers in patients receiving anticoagulation therapy.
Source: Clinical Gastroenterology and Hepatology - October 16, 2016 Category: Gastroenterology Authors: Kathryn F. Flack, Jay Desai, Jennifer M. Kolb, Prapti Chatterjee, Lars C. Wallentin, Michael Ezekowitz, Salim Yusuf, Stuart Connolly, Paul Reilly, Martina Brueckmann, John Ilgenfritz, James Aisenberg Source Type: research

Novel Oral Anticoagulants and Gastrointestinal Bleeding: a Case for Cardiogastroenterology
With the rapidly evolving cardiology drug pipeline for treatment of acute coronary syndrome (ACS), gastroenterologists have witnessed the emergence of a new population of patients who are vulnerable to gastrointestinal (GI) bleeding: the chronic cardiac patient. ACS, causing myocardial infarction (MI) and unstable angina, and atrial fibrillation are the signature conditions of the chronic cardiac patient. The morbidity and mortality of ACS is significant. Chronic cardiac patients are prescribed complex antithrombotic therapy (CAT) (ie, aspirin [ASA] plus a thienopyridine, eg, clopidogrel [Plavix; Bristol-Myers Squibb/Sanof...
Source: Clinical Gastroenterology and Hepatology - January 23, 2013 Category: Gastroenterology Authors: Neena S. Abraham Tags: Comment From the Editor Source Type: research